Drugs / MK-8527
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT07600775 | Jul 2026 → Jan 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07661108 | Jun → Oct 2026 expected | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07528508 | May → Aug 2026 overdue | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07025551 | Sep 2025 → Feb 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07063238 | Aug → Dec 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06893081 | Apr → Jun 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06580587 | Apr 2025 → Mar 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06826989 | Mar → Jun 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06816043 | Feb → Jun 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06295796 | Jun 2024 → Jan 2025 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06783192 | Aug → Oct 2023 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05494736 | Nov 2022 → Jan 2024 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03615183 | Feb → Sep 2019 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07850609 | Oct 2026 → Dec 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06045507 | Nov 2023 → Dec 2024 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07071623 | Nov 2025 → Oct 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07044297 | Jul 2025 → Jul 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Merck Sharp & Dohme LLC | MSD Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development msd.com ↗ |
| 2026-07-24 | Merck Sharp & Dohme LLC | Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development merck.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07044297 ↗ |
| Known as | Alimatravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07850609 ↗ |
| Action | Inhibit | “Nucleoside Reverse Transcriptase Translocation Inhibitor” PMID 41830320 ↗ May 2026 |
| Modality | Small molecule | “MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor” PMID 41830320 ↗ May 2026 |
| Route | Oral | “Single oral capsule” NCT03615183 ↗ |